November 1, 2024
Inherited Retinal Disease Articles
October 1, 2024
Clinical Trial Download: The Potential of Optogenetic Therapy
By Yasha Modi, MD , Allen C. Ho, MD, Sulagna Bhattacharya, MBA
July 19, 2024
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
By Jennifer Ford, senior managing editor
July 18, 2024
TEASE-3 Study Data on Oral Therapy for Stargardt Disease Presented at ASRS
By Jennifer Ford, senior managing editor
July 10, 2024
Optogenetic Therapy Shows Promise for Retinitis Pigmentosa
July 1, 2024
Foundation Fighting Blindness Partners With PreventionGenetics
By Rochelle Nataloni, contributing writer
July 1, 2024
Ocugen Meets Dosing Milestone in Stargardt Disease Trial
By Rochelle Nataloni, contributing writer
July 1, 2024
CRISPR Trial Demonstrates Potential Advances for Inherited Blindness
By Rochelle Nataloni, contributing writer
July 1, 2024
Sickle Cell Drug Shows Promise in Stabilizing Vision in Rare Genetic Disease
June 1, 2024
First Patient Dosed in Retinitis Pigmentosa Intravitreal Treatment Trial
By Rochelle Nataloni, contributing writer
May 1, 2024
Overview of Retinal Prosthesis and Future Directions
By Jade Y. Moon, MD, Richard N. Sather III, BS, Sandra R. Montezuma, MD
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
By Jim Gallagher, senior managing editor
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
February 16, 2024
Retinal Physician eUpdate - February 16, 2024
By Steve Lenier
November 1, 2023
History, Symptoms, and Management of Coats Disease
By Jay K. Rathinavelu, BSE, Grant A. Justin, MD, Lejla Vajzovic, MD, FASRS
November 1, 2023
SUBSPECIALTY NEWS: Ryzumvi approved, positive gene therapy data, Syfovre receives J code, and more.
By Rochelle Nataloni, contributing writer
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
An Update on Stem Cell Therapy for Retinal Diseases
By Samuel R. Feldman, MD, Glenn C. Yiu, MD, PhD, Susanna S. Park, MD, PhD
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
By Rochelle Nataloni, contributing writer
March 1, 2023
Key Questions at the Heart of Inherited Retinal Disease Gene Therapy Innovation
By Thomas A. Mendel, MD, PhD
March 1, 2023
A Basic Primer on Gene Therapy
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
March 1, 2023
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
Interpreting OCT Images Showing Pisciform Fundus Flecks
By Marianeli Rodriguez, MD, PhD
January 1, 2023
Clinical Trial Update January/February 2023
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
August 1, 2022
Suprachoroidal Drug Delivery Technology
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
August 1, 2022
SUBSPECIALTY NEWS: Data presented on THR-149 and THR-687 for DME, pegcetacoplan NDA submitted, AREDS2 benefit confirmed, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
Oral Drug Pipeline for Retinal Disease
By Charles DeBoer, MD, PhD, Suzanne Michalak, MD, Ehsan Rahimy, MD
July 1, 2022
SUBSPECIALTY NEWS: RetinAI gets FDA clearance, suprachoroidal therapy update, GA trial data, and more.
By Rochelle Nataloni, contributing writer
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
May 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy lesion growth slowed with pegcetacoplan, new data on extended-duration therapies, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
CLINICAL TRIAL DOWNLOAD: Update on Advances Toward Therapeutics in Inherited Retinal Dystrophies
By Yasha Modi, MD , Peter Y. Zhao, MD, Thiran Jayasundera, MD, MS
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
Advertisement
Recommendations
Advertisement